[go: up one dir, main page]

WO2006016275A3 - Gastrin-specific interfering rna - Google Patents

Gastrin-specific interfering rna

Info

Publication number
WO2006016275A3
WO2006016275A3 PCT/IB2005/002686 IB2005002686W WO2006016275A3 WO 2006016275 A3 WO2006016275 A3 WO 2006016275A3 IB 2005002686 W IB2005002686 W IB 2005002686W WO 2006016275 A3 WO2006016275 A3 WO 2006016275A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastrin
molecules
rnai
specific interfering
rnai molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002686
Other languages
French (fr)
Other versions
WO2006016275A2 (en
Inventor
Susan A Watson
Anna Grabowska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aphton Corp
Original Assignee
Aphton Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aphton Corp filed Critical Aphton Corp
Priority to AU2005270917A priority Critical patent/AU2005270917A1/en
Priority to EP05775595A priority patent/EP1778841A2/en
Priority to CA002576576A priority patent/CA2576576A1/en
Publication of WO2006016275A2 publication Critical patent/WO2006016275A2/en
Publication of WO2006016275A3 publication Critical patent/WO2006016275A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides gastrin-specific interfering ribonucleic acid (RNAi) molecules that down-regulate the gastrin hormone gene. The RNAi molecules of the invention are double-stranded RNA molecules that can include modified bases and non-phosphate linkages between the bases. The complementary strands of the RNAi molecules of the invention can be linked by a nucleotide chain or by non-nucleotide linkers. The RNAi molecules of the invention can be formulated in pharmaceutical compositions useful in a method for treating gastrin-mediated diseases or conditions including gastrin-mediated tumors, GERD, Zollinger-Ellison syndrome, hypergastrinemia, pernicious anemia, gastric ulceration, duodenal ulceration, and H. pylori infection.
PCT/IB2005/002686 2004-08-11 2005-08-10 Gastrin-specific interfering rna Ceased WO2006016275A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2005270917A AU2005270917A1 (en) 2004-08-11 2005-08-10 Gastrin-specific interfering RNA
EP05775595A EP1778841A2 (en) 2004-08-11 2005-08-10 Gastrin-specific interfering rna
CA002576576A CA2576576A1 (en) 2004-08-11 2005-08-10 Gastrin-specific interfering rna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60069604P 2004-08-11 2004-08-11
US60/600,696 2004-08-11

Publications (2)

Publication Number Publication Date
WO2006016275A2 WO2006016275A2 (en) 2006-02-16
WO2006016275A3 true WO2006016275A3 (en) 2006-05-18

Family

ID=35759261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002686 Ceased WO2006016275A2 (en) 2004-08-11 2005-08-10 Gastrin-specific interfering rna

Country Status (5)

Country Link
EP (1) EP1778841A2 (en)
KR (1) KR20070062515A (en)
AU (1) AU2005270917A1 (en)
CA (1) CA2576576A1 (en)
WO (1) WO2006016275A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4689597B2 (en) 2003-03-28 2011-05-25 レセプター バイオロジックス インク． Gastrin hormone immunoassay
US8889640B1 (en) * 2008-06-20 2014-11-18 Jill P. Smith Composition and method for the treatment of gastrin mediated cancers
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
CN111050789A (en) 2017-06-15 2020-04-21 癌症进展有限公司 Compositions and methods for inducing humoral and cellular immunity against tumors and cancer
US20240398917A1 (en) * 2021-01-13 2024-12-05 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010180A1 (en) * 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
WO2004042061A1 (en) * 2002-11-08 2004-05-21 Klaus Strebhardt Pharmaceutical composition for suppressing undesired gene expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010180A1 (en) * 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
WO2004042061A1 (en) * 2002-11-08 2004-05-21 Klaus Strebhardt Pharmaceutical composition for suppressing undesired gene expression

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRABOWSKA A ET AL: "Downregulation of the gastrin gene using small interfering RNA", REGULATORY PEPTIDES, vol. 122, no. 1, September 2004 (2004-09-01), & 15TH INTERNATIONAL SYMPOSIUM ON REGULATORY PEPTIDES; TOULOUSE, FRANCE; SEPTEMBER 19 -22, 2004, pages 46, XP009061814, ISSN: 0167-0115 *
SINGH P ET AL: "TUMORIGENICITY OF A HUMAN COLON CANCER CELL LINE IS SIGNIFICANCE REDUCED IN VIVO, IN THE PRESENCE OF COLON CANCER CELLS OVEREXPRESSING ANTISENSE GASTRIN MRNA: ROLE OF INHIBITORY (ENDOCRINE) FACTORS IN THE OBSERVED BYSTANDER EFFECTS", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, US, vol. 114, no. 4, PART 2, 15 April 1998 (1998-04-15), pages A680, XP008056925, ISSN: 0016-5085 *
SMITH J P ET AL: "Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer", CANCER LETTERS, NEW YORK, NY, US, vol. 135, no. 1, 8 January 1999 (1999-01-08), pages 107 - 112, XP002357825, ISSN: 0304-3835 *
TAKHAR A S ET AL: "The role of gastrin in colorectal carcinogenesis.", THE SURGEON : JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND. OCT 2004, vol. 2, no. 5, October 2004 (2004-10-01), pages 251 - 257, XP009061845, ISSN: 1479-666X *
WATSON S ET AL: "GASTRIN INHIBITION INCREASES THE POTENCY OF CYTOTOXIC AGENTS IN PANCREATIC CANCER", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, US, vol. 122, no. 4, SUPPL 1, April 2002 (2002-04-01), pages A241, XP008056958, ISSN: 0016-5085 *

Also Published As

Publication number Publication date
CA2576576A1 (en) 2006-02-16
WO2006016275A2 (en) 2006-02-16
EP1778841A2 (en) 2007-05-02
AU2005270917A1 (en) 2006-02-16
KR20070062515A (en) 2007-06-15
AU2005270917A8 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
ATE557088T1 (en) PANCREASIC ISLAND MICRORNA AND METHOD FOR SUPPRESSING IT
WO2007031877A3 (en) Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
SI2258847T1 (en) Futher novel forms of interfering RNA molecules
WO2006119266A3 (en) Human micrornas and methods for inhibiting same
WO2007051045A3 (en) Compositions and methods for inhibiting expression of huntingtin gene
WO2004022714A3 (en) Organic species that facilitate charge transfer to or from nanostructures
CA2513809A1 (en) Lipophilic derivatives of double-stranded ribonucleic acid
WO2006026388A3 (en) Single-primer nucleic acid amplification methods
WO2009013620A3 (en) Homologous recombination
EP1167461A3 (en) Process for conditioning organic pigments
WO2005089929A3 (en) Modified surfaces as solid supports for nucleic acid purification
DE60234369D1 (en) MANIPULATED MATRICES AND THEIR USE IN SINGLE PRIMER AMPLIFICATION
WO2005042716A3 (en) Nucleic acid binding oligonucleotides
WO2006066203A3 (en) Small interfering rna (sirna) molecules for modulating superoxide dismutase (sod)
ATE528397T1 (en) GENE OVEREXPRESSED IN CANCER
MX2009000656A (en) Sdf-i binding nucleic acids.
WO2006016275A3 (en) Gastrin-specific interfering rna
WO2008009477A3 (en) Means for inhibiting the expression of protein kinase 3
WO2002083943A3 (en) Microarray method for enriching dna fragments from complex mixtures
Lou et al. Oligonucleotides containing a piperazino-modified 2′-amino-LNA monomer exhibit very high duplex stability and remarkable nuclease resistance
WO2002061110A8 (en) Nucleic acid derivatives
WO2005110067A3 (en) Method and compositions for rna interference
WO2005123956A3 (en) Rapid production of oligonucleotides
WO2009105691A3 (en) Uses of pentamidine and related compounds
EP1479783A3 (en) PCR amplification method, pcr primer set, pcr amplification product, and method for detection of nucleic acid using the amplification method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2576576

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200580027254.1

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007525384

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005270917

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005775595

Country of ref document: EP

Ref document number: 1731/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020077005675

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005270917

Country of ref document: AU

Date of ref document: 20050810

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005270917

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005775595

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005775595

Country of ref document: EP